Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Tributyrin is a triglyceride form of butyric acid, a short-chain fatty acid (SCFA) produced naturally in the colon by bacterial fermentation of dietary fibers. There is a growing body of preclinical and early clinical research suggesting its potential benefit in inflammatory bowel diseases (IBD) such as Crohn's Disease. The rationale is based on butyrate's role as a primary energy source for colonocytes, its ability to enhance intestinal barrier function, and its anti-inflammatory properties through modulation of immune response and inhibition of NF-κB signaling.

Animal studies have shown that oral or rectal administration of butyrate or tributyrin can reduce inflammation and promote mucosal healing in models of colitis. Some small-scale human studies and case reports have reported improvements in symptoms and markers of inflammation in IBD patients treated with butyrate enemas or oral tributyrin, but these studies are limited in size and quality.

Overall, while the mechanistic basis for tributyrin supplementation in Crohn's Disease is scientifically plausible and supported by preclinical data, robust, large-scale clinical trials in humans are lacking. The evidence supporting its clinical use is therefore preliminary (rated 2/5), and tributyrin should not be considered a primary or stand-alone therapy for Crohn's Disease at this time. Further research is needed to clarify dosing, efficacy, and safety in this patient population.

More about tributyrin
More about Crohn's Disease

Other ingredients used for Crohn's Disease

Other health conditions supported by tributyrin

Products containing tributyrin